Document is current

Article History

First Online: 29 September 2026

Ethics

Competing interests: Grants: MSD, Merck and Guardant Health. Honoraria: Taiho Oncology, MSD, Merck, Dr Reddy’s. Consulting or advisory role: Starpharma (Inst), Greywolf Therapeutics, Daiichi Sankyo and Kivu Biosciences. Participation on data safety and monitor boards: Starpharma, Relay Therapeutics, IDEAYA Biosciences, Innovent Biologics, Greywolf Therapeutics, Nested Therapeutics, Carina Biotech, ImmVirX, MediLink Therapeutics, Kivu Biosciences and BeOne. Research funding: Starpharma (Inst), Relay Therapeutics (Inst), ALX Oncology (Inst), IDEAYA Biosciences (Inst), Innovent Biologics (Inst), Greywolf Therapeutics (Inst), MSD (Inst), Regeneron (Inst), Bristol Myers Squibb (Inst), AbbVie (Inst), AVEO (Inst), Bayer (Inst), Merus (Inst), Nested Therapeutics (Inst), Bristol Myers Squibb (Inst), Carina Biotech (Inst), ImmVirX (Inst), AVEO (Inst), Daiichi Sankyo/UCB Japan (Inst), MediLink Therapeutics (Inst), Covus Therapeutics (Inst), OncoNano Inc (Inst), Kivu Biosciences, Guardant Health (Inst) and BeOne (Inst). Travel, accommodation and expenses: Starpharma and Innovent Biologics.